Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Purdue Research Park-based Life Sciences Firm Receives $300,000 NIH Grant

Published: Friday, November 16, 2012
Last Updated: Friday, November 16, 2012
Bookmark and Share
A life sciences company whose technology could help researchers develop drug candidates to battle cancer, diabetes, and immune system and neurological disorders has received a $300,000 grant.

Tymora Analytical Operations LLC, a Purdue Research Park-based company, received the SBIR Phase I grant to optimize and strengthen its PolyMAC product. The technology promotes the discovery of new disease targets in laboratory settings. It is based on research by W. Andy Tao, associate professor in Purdue's Department of Biochemistry. The company licensed the technology through the Purdue Office of Technology Commercialization.

Anton Iliuk, president and chief technology officer, said PolyMAC could help determine whether a potential drug in development is focused on the intended disease targets. He described how the NIH funding will benefit Tymora Analytical Operations' efforts.

"Products currently available on the market typically see only the tip of the iceberg of a disease," he said. "PolyMAC technology allows a researcher to dive deeper into the complicated disease network to find the most optimal and promising treatment targets."

Iliuk said the company's focus is to strengthen efforts in university and industrial laboratories to find more effective, efficient drug treatment candidates for cancer, immunological and infectious illnesses, and diabetes.

Tymora Analytical Operations received a $150,000 SBIR Phase I grant from the NIH to develop an application for its pIMAGO platform earlier in 2012. It also received a $150,000 SBIR Phase I grant from the National Science Foundation in 2011, and $20,000 from the Purdue-administered Emerging Innovations Fund in 2012.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cell-Detection System Promising for Medical Research, Diagnostics
Researchers are developing a system that uses tiny magnetic beads to quickly detect rare types of cancer cells circulating in a patient's blood.
Thursday, October 03, 2013
Bird Flu Expert Working on Vaccine that Protects Against Multiple Strains
As the bird flu outbreak in China worsens, a Purdue University expert is working on vaccines that offer broader protection against multiple strains of the virus.
Friday, May 10, 2013
Discovery Points to New Approach to Fight Dengue Virus
Researchers have discovered that rising temperature induces key changes in the dengue virus when it enters its human host, suggests new approach for designing vaccines against the aggressive mosquito-borne pathogen.
Monday, April 15, 2013
Research Reveals how Antibodies Neutralize Mosquito-Borne Virus
Researchers have learned the precise structure of the mosquito-transmitted chikungunya virus pathogen while it is bound to antibodies, showing how the infection is likely neutralized.
Wednesday, April 03, 2013
Researcher Taking Shot at Flu Vaccine That's More Effective, Easier to Make
In the midst of an unusually deadly flu season and armed with a vaccine that only offers partial protection, researcher is working on a flu vaccine that overcomes the need to predict which strains will hit each year.
Monday, February 11, 2013
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!